Company(ies): OnyVax
Principal Therapy Area: Cancer
£195 / $340 / €245
Online, PDF
Onyvax-P is a therapeutic cancer vaccine consisting of a combination of three inactivated cell lines that are representative of different stages of prostate cancer (PCA). Using a combination of cell lines ensures that a broad range of PCA antigens are presented to the immune system and this decreases the risks of the tumour being able to mutate and become resistant to the therapy.
Onyvax-P is being developed for asymptomatic patients, that is, those with minimal disease burden. The more advanced the cancer, the more immunosuppressed the patient becomes and the less likely he will respond to vaccine therapy. This strategy increases the chances of clinical success.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Cost-effective collections
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for direct_sales@espicom.com